Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Fig. 2

1) Flow cytometry analysis on Day0 showing blasts cells, gated on CD45/side scatter display, are positive for CD19 and CD38 and negative for CD20 and CD22. On Day826, at relapse and after the exposure to blinatumomab, blasts cells have become negative for CD19. 2) Bone marrow biopsy on D826: the bone marrow contained an interstitial infiltrate of blastic cells (arrows) (A), which were positive for PAX5 (B), BCL2 (C) while only a minority were faintly positive for CD19 (D).

Back to article page